Does giritinib need to be taken long-term?

Gilitinib (Gilteritinib) is a targeted drug for certain types of acute myeloid leukemia (AML) and usually needs to be taken long-term. The long-term nature of its treatment mainly depends on the following factors:

Chronic nature of AML: AMLis generally considered a chronic disease, and the disease may relapse even after patients achieve a state of complete remission. Therefore, giritinib, as a maintenance treatment drug, may need to be taken long-term to control the progression of the disease.

Treatment goals: The goal of treating AML with giritinib is to control the proliferation and survival of leukemia cells and prolong the survival of patients. To achieve this, patients typically need to continue taking giritinib during treatment.

Maintaining remission: For patients who achieve complete remission, maintenance therapy can help maintain remission and reduce the risk of leukemia cells relapse. Therefore, long-term administration of giritinib may be necessary to maintain patients' disease control status.

Disease Characteristics: Different patients may have AML characteristics and responses to treatment that vary, so treatment options may vary from person to person. Some patients may require long-term treatment with gilitinib to control disease progression, while others may achieve complete remission in a shorter period of time and discontinue drug treatment.

In summary, gilitinib usually needs to be taken long-term to controlAML progression and maintain the patient's disease control status. Patients should strictly follow the drug usage instructions according to the doctor's advice, and conduct regular review and monitoring to ensure the effectiveness and safety of the treatment. At the same time, doctors will also adjust the treatment plan according to the patient's disease status and treatment response to achieve the best treatment effect.